Natacyn®
Natamycin 5% · ophthalmic suspension
Antifungal
Approved uses
Fungal keratitis, including Fusarium solani
One drop into the conjunctival sac at hourly or two-hourly intervals; frequency can usually be reduced to one drop 6 to 8 times daily after the first 3 to 4 days, and therapy should generally continue 14 to 21 days or until active fungal keratitis resolves
Gains 1.8 lines of acuity over voriconazole by 3 months, 4.1 lines in Fusarium ulcers.
Fungal blepharitis and conjunctivitis
4 to 6 daily applications may be sufficient
OFF-LABELNot in the FDA label for this product
Recalcitrant deep fungal keratitis, intrastromal injection
10 mcg/0.1 mL intrastromal, repeated as needed, with topical 5% every 4 hours until the ulcer heals
Single-center trial · n=60
Single-center trial in 60 eyes with microbiologically proven ulcers larger than 2 mm, deeper than half the stroma, and unresponsive to 2 weeks of topical therapy, allocated 20 per arm to intrastromal natamycin 10 mcg/0.1 mL, voriconazole 50 mcg/0.1 mL, or amphotericin B 5 mcg/0.1 mL. Mean time to healing was 34 days (SD 5.2) with natamycin versus 36.1 days (SD 4.8) and 39.2 days (SD 7.2), P = 0.02, with successful healing in 95%, 95%, and 90% and deep vascularization after healing more common in the amphotericin B arm (55% versus 26% and 31%, P = 0.02). Every arm received an intrastromal injection on top of topical therapy, so the trial cannot show whether adding an injection beats topical therapy alone. The authors call it a randomized controlled trial; PubMed indexes it as a journal article only.
Contraindications
History of hypersensitivity to any component of the formulation.
5% (50 mg/mL) suspension, 15 mL fill in an amber glass bottle, dropper packaged separately
Tetraene polyene antibiotic derived from Streptomyces natalensis, with in vitro activity against a variety of yeast and filamentous fungi, including Candida, Aspergillus, Cephalosporium, Fusarium, and Penicillium. The mechanism of action appears to be binding to the sterol moiety of the fungal cell membrane, and the polyene-sterol complex alters membrane permeability to produce depletion of essential cellular constituents. Activity against fungi is dose-related, and natamycin is predominantly fungicidal. Topical administration appears to produce effective concentrations within the corneal stroma but not in intraocular fluid, and natamycin is not effective in vitro against gram-positive or gram-negative bacteria.
Warnings & Precautions
- Not for injection: For topical ophthalmic use only.
- Diagnostic confirmation: Initial and sustained therapy should follow the clinical diagnosis, smear and culture of corneal scrapings, and drug response, with in vitro activity against the responsible fungus determined whenever possible.
- Endophthalmitis: Effectiveness as a single agent in fungal endophthalmitis is not established.
- Limited intraocular penetration: Topical administration appears to produce effective concentrations within the corneal stroma but not in intraocular fluid, and rabbit studies found no measurable compound in aqueous humor or sera at a stated assay sensitivity no greater than 2 mg/mL.
- Failure to improve: Failure of keratitis to improve after 7 to 10 days suggests the infection may be caused by a microorganism not susceptible to natamycin; continued therapy should be based on clinical re-evaluation and additional laboratory studies.
- Adherence and retention: Adherence of the suspension to areas of epithelial ulceration or retention of the suspension in the fornices occurs regularly.
- No antibacterial activity: Inactive in vitro against gram-positive and gram-negative bacteria.
- Dropper contamination: Touching the dropper tip to any surface can contaminate the suspension.
- Container damage: Use only if the container is undamaged.
- Contact lens wear: Lenses are not to be worn while signs and symptoms of fungal blepharitis, conjunctivitis, or keratitis are present.
Common Side Effects
The following events have been identified during post-marketing use in clinical practice: allergic reaction, change in vision, chest pain, corneal opacity, dyspnea, eye discomfort, eye edema, eye hyperemia, eye irritation, eye pain, foreign body sensation, paresthesia, and tearing. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.
Pregnancy: No animal reproduction studies have been conducted; whether the drug can cause fetal harm or affect reproductive capacity is unknown, so give only if clearly needed.
Lactation: It is not known whether these drugs are excreted in human milk, so caution should be exercised when natamycin is administered to a nursing woman.
Safety and effectiveness in pediatric patients have not been established.